| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 29.631 | 8.050 | - | 0 | 448 | 3.338 | 210 | 0 |
| Total Income - EUR | - | - | 29.744 | 9.240 | - | 0 | 448 | 3.338 | 210 | 2 |
| Total Expenses - EUR | - | - | 7.641 | 20.072 | - | 5.813 | 2.395 | 8.591 | 8.026 | 9.678 |
| Gross Profit/Loss - EUR | - | - | 22.102 | -10.832 | - | -5.813 | -1.947 | -5.254 | -7.817 | -9.676 |
| Net Profit/Loss - EUR | - | - | 21.806 | -10.923 | - | -5.813 | -1.960 | -5.354 | -7.819 | -9.676 |
| Employees | - | - | 1 | 2 | - | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Pharmacokinetics Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 3.234 | 5.132 | - | 471 | 35 | 0 | 0 | 0 |
| Current Assets | - | - | 24.238 | 11.632 | - | 2.675 | 3.049 | 2.973 | 2.364 | 1.750 |
| Inventories | - | - | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | 1.688 | 2.906 | - | 2.496 | 2.936 | 2.552 | 2.257 | 1.725 |
| Cash | - | - | 22.551 | 8.726 | - | 179 | 114 | 421 | 107 | 25 |
| Shareholders Funds | - | - | 21.850 | 10.526 | - | -14.016 | -15.665 | -22.809 | -30.559 | -40.064 |
| Social Capital | - | - | 44 | 43 | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 5.623 | 6.238 | - | 17.162 | 18.750 | 25.782 | 32.923 | 41.813 |
| Income in Advance | - | - | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6310 - 6310" | |||||||||
| CAEN Financial Year |
6311
|
|||||||||
Comments - Pharmacokinetics Srl